[Panel webinar] Overcoming the clinical development and delivery challenges of oncology therapies

Cancer treatment research is moving forward at a rapid pace. With more than 12.5 million new cases of cancer being identified worldwide each year, improved diagnosis and treatment is essential, yet oncology clinical research remains complex. Special consideration needs to be given to the technical and organizational controls that will ensure safety and minimize risk.

Choosing the right contract development and management organization (CDMO) for the production of highly potent clinical trial material is key. This allows organizations to successfully manage upscale of products throughout the clinical phases and through to successful commercialization.

In this webinar, learn how clinical trial sponsors can reduce complexity and manage their drug development challenges to optimize the supply chain for success, maintain clinical flexibility and ensure the highly specialized medicines are delivered to patients in need at speed.

Register for this webinar to:

• Understand why choosing the right CDMO is key for the production of clinical trial material.
• Learn how to overcome manufacturing challenges that can have a profound impact on a projects critical parameters, particularly lead time and cost.
• Examine innovative and improved packaging tools to address the complexities of traditional packaging methods.
• Overcome logistical challenges associated with storage and distribution of oncology medicines and understand the options available to safeguard supply chain custody of drug products.

Presenters:

David O'Connell, Director of Scientific Affairs at PCI

After graduating from Glasgow Caledonian University in Scotland with a Bachelor of Science degree in Applied Bioscience, O’Connell spent seven years as a Supervisory Scientist working for Aptuit in Edinburgh, Scotland, before moving to Penn Pharma as Head of Formulation Development in 2009. Here he played a vital part in the design of the potent Contained Manufacturing Facility (CMF), which won the ISPE Facility of the Year award in 2014 for Facility Integration. In 2014 PCI acquired Penn Pharma and O’Connell took on the role of Director, Pharmaceutical Development at the PCI site in Tredegar, Wales, UK. In his current role, O’Connell aids clients with formulation development, technical transfer and scale-up of solid oral, oral liquid and semi-solid products for clinical trials and/or commercialization. He also has line management responsibility for the Validation Team (Process, Equipment and Facilities) and the Quotes proposal preparation group.

Aldyth Smith, Director Supply Chain at PCI

Aldyth Smith has over 30 years’ experience within the pharmaceutical industry and has held senior leadership roles within clinical and commercial operations; planning and procurement, logistics and distribution, project management and commercial account management. Smith joined PCI in 1993. Throughout her career she has shown a clear passion for customer satisfaction, and currently holds the role of Director of Supply Chain at the PCI Tredegar facility in Wales, UK. Smith is responsible for delivering a high-level customer experience, driving on time delivery by providing an end-to-end service to our global customers.

Rachel Griffiths, Associate Director, Technical Services at PCI

Rachel Griffiths has previously held leadership roles in Operations and Technical Support. Her current role at PCI involves overseeing the installation and validation of new facilities at the company’s Bridgend site and the implementation of new technologies and innovations in controlled-temperature packaging, storage and distribution services. With a degree in Microbiology and Virology, Griffiths is the Biological Safety Officer for the Bridgend site and also has previous experience as a development scientist, a technical support scientist and a product support specialist.

The webinar will take place at:

• 4pm CET
• 10am EDT
• 7am PDT